Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, developed by Syrrx, a company which was acquired by Takeda Pharmaceutical Company in 2005. Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.
Alogliptin is a dipeptidyl peptidase-4 inhibitor that decreases blood sugar similar to the other.
Adverse events include mild hypoglycemia based on clinical studies. It may cause severe joint pain.
Alogliptin is not associated with increased weight, increased risk of cardiovasular events, or heart failure.
RADIO STATION | GENRE | LOCATION |
---|---|---|
African Online Radio | World,World Asia,World Africa | Kenya |
Ghetto Radio 89.5 | Varied | Kenya |
KASS online | World Africa | Kenya |
KamemeFM | World Africa | Kenya |
apana990 | Bollywood | Kenya |